TrialCirculation research2017

Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.

Javed Butler et al.PubMed ↗Publisher ↗

No numbers read from the abstract.